Aeglea Bio Therapeutics Inc  

(Public, NASDAQ:AGLE)   Watch this stock  
Find more results for AGLE
+0.29 (4.77%)
Real-time:   12:48PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.04 - 6.37
52 week 2.81 - 8.14
Open 6.05
Vol / Avg. 26,421.00/89,902.00
Mkt cap 106.02M
P/E     -
Div/yield     -
EPS -1.83
Shares 16.64M
Beta     -
Inst. own 64%
Dec 14, 2017
Aeglea Bio Therapeutics Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -624.42% -468.84%
Operating margin -634.26% -473.34%
EBITD margin - -470.48%
Return on average assets -49.48% -41.05%
Return on average equity -53.48% -106.47%
Employees 45 -
CDP Score - -


901 S. Mopac Expressway Ste. 250, Barton Oaks Plaza One
AUSTIN, TX 78746
United States - Map
+1-512-9422935 (Phone)
+1-512-8725121 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

Officers and directors

Armen B Shanafelt Ph.D. Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Anthony G. Quinn M.D. Ph.D. Interim Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
George Georgiou Ph.D. Co-Founder, Director
Age: 56
Bio & Compensation  - Reuters
Charles N. York II Chief Financial Officer, Vice President
Age: 39
Bio & Compensation  - Reuters
Henry L. Hebel Vice President - Product Development
Age: 44
Bio & Compensation  - Reuters
Scott W. Rowlinson Vice President - Research
Age: 48
Bio & Compensation  - Reuters
Joseph E. Tyler Vice President - Manufacturing
Age: 65
Bio & Compensation  - Reuters
Suzanne Bruhn Director
Bio & Compensation  - Reuters
Russell J. Cox Independent Director
Age: 54
Bio & Compensation  - Reuters
Sandesh Mahatme Independent Director
Age: 52
Bio & Compensation  - Reuters